Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b4 + BNT162b2
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
BNT162b4 + BNT162b2 is an investigational combination mRNA vaccine developed by BioNTech and Pfizer for the prevention of COVID-19. This combination therapy pairs BNT162b2 (Comirnaty), a nucleoside-modified mRNA vaccine encoding the SARS-CoV-2 spike protein, with BNT162b4, a next-generation vaccine candidate encoding conserved non-spike proteins including the nucleocapsid (N), membrane (M), and ORF1ab proteins. While BNT162b2 primarily induces neutralizing antibodies against the spike protein, BNT162b4 is designed to enhance and broaden T-cell mediated immunity by targeting viral proteins that are more conserved across different SARS-CoV-2 variants. The combination is being evaluated as a booster to provide more durable and comprehensive protection against evolving strains of the virus.
- Other names
- BNT162b4 + BNT162b2 BivalentBNT162b4 + BNT162b2 Monovalent
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)M protein (SARS-CoV-2 membrane protein)NSP3 (SARS-CoV-2 non-structural protein 3)
Beyond the preview
Go deeper on BNT162b4 + BNT162b2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b4 + BNT162b2.